Athernal Bio
United Kingdom
- Cambridge
- 02/10/2025
- Unknown
- $4,718,630
Developing targeted immunotherapies to treat high-risk clonal haematopoiesis (CH)—the precursor to blood cancers—so we can stop cancer before it starts.
- Industry Biotechnology Research
- Website https://www.athernalbio.com/
- LinkedIn https://www.linkedin.com/company/athernal-bio/
Related People
Colin FreundFounder
United States -
New York City Metropolitan Area
C-level executive with experience in both private and public biotechnology companies, with 18 years' experience leading multinational teams that drive revenue generation and corporate value creation: company leadership (including venture fundraising); strategic planning, business/corporate development and M&A ($500M+ in multiple licensing/M&A transactions); corporate restructuring; alliance management; commercial development and product launch preparation; supply chain optimization; organizational development; investor relations/fundraising; and business interface on regulatory strategy in the USA, Europe and Asia.
Standard Kernel Co. | $20,000,000 | (Mar 12, 2026)
Talvy | $2,000,000 | (Mar 11, 2026)
Sigma360 | $17,000,000 | (Mar 11, 2026)
R2 Wireless | $5,000,000 | (Mar 11, 2026)
Verdant Impact | $3,000,000 | (Mar 11, 2026)
Lux Aeterna | $10,000,000 | (Mar 11, 2026)
Amigo | $11,000,000 | (Mar 11, 2026)
Axiom Trust Company | $11,800,000 | (Mar 11, 2026)
Sandbar | $23,000,000 | (Mar 11, 2026)
Jazz | $61,000,000 | (Mar 11, 2026)
PactFi | $25,000,000 | (Mar 11, 2026)